Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A Bookman

Showing results (21-30 of 102) with videos related to

Pageof 11
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|August 21, 2010
Pillars article: the CD4 and CD8 T cell surface antigens are associated with the internal membrane tyrosine-protein kinase p56lck. 1994André Veillette, Michael A Bookman, Eva M Horak, et al.
Gynecologic Oncology|December 26, 2001
Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group studySteven C Plaxe, John A Blessing, Michael A Bookman, et al.
Gynecologic Oncology|March 21, 2007
A phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group studyDeborah K Armstrong, Michael A Bookman, William McGuire, et al.
Gynecologic Oncology|January 31, 2004
Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group studyKatherine Y Look, Michael A Bookman, Jessie Schol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2003
Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology GroupMichael A Bookman, Kathleen M Darcy, Daniel Clarke-Pearson, et al.
Gynecologic Oncology|October 31, 2008
Phase I trial of the treatment of high-risk endometrial cancer with concurrent weekly paclitaxel and cisplatin and whole abdominal radiation therapy: a Gynecologic Oncology Group studyD Scott McMeekin, Joan L Walker, Ellen M Hartenbach, et al.
Gynecologic Oncology|April 30, 2017
Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancerMichael A Bookman, Jerzy E Tyczynski, Janet L Espirito, et al.
Gynecologic Oncology|March 25, 2014
Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: an exploratory study of the gynecologic oncology groupKrishnansu S Tewari, James J Java, Troy A Gatcliffe, et al.
Investigational New Drugs|November 27, 2002
Phase I escalation of gemcitabine combined with protracted oral etoposide in gynecologic malignancies: A Gynecologic Oncology Group studyAgustin A Garcia, Michael A Bookman, Lorna Rodriguez-Rodriguez, et al.
Cancer|September 24, 2010
Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a Gynecologic Oncology Group studyRichard J Zaino, Mark F Brady, Subodh M Lele, et al.
Pageof 11

Showing results (21-30 of 102) with videos related to

Sort By:
Pageof 11
Journal of Immunology (Baltimore, Md. : 1950)|August 21, 2010
Pillars article: the CD4 and CD8 T cell surface antigens are associated with the internal membrane tyrosine-protein kinase p56lck. 1994André Veillette, Michael A Bookman, Eva M Horak, et al.
Gynecologic Oncology|December 26, 2001
Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group studySteven C Plaxe, John A Blessing, Michael A Bookman, et al.
Gynecologic Oncology|March 21, 2007
A phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group studyDeborah K Armstrong, Michael A Bookman, William McGuire, et al.
Gynecologic Oncology|January 31, 2004
Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group studyKatherine Y Look, Michael A Bookman, Jessie Schol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2003
Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology GroupMichael A Bookman, Kathleen M Darcy, Daniel Clarke-Pearson, et al.
Gynecologic Oncology|October 31, 2008
Phase I trial of the treatment of high-risk endometrial cancer with concurrent weekly paclitaxel and cisplatin and whole abdominal radiation therapy: a Gynecologic Oncology Group studyD Scott McMeekin, Joan L Walker, Ellen M Hartenbach, et al.
Gynecologic Oncology|April 30, 2017
Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancerMichael A Bookman, Jerzy E Tyczynski, Janet L Espirito, et al.
Gynecologic Oncology|March 25, 2014
Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: an exploratory study of the gynecologic oncology groupKrishnansu S Tewari, James J Java, Troy A Gatcliffe, et al.
Investigational New Drugs|November 27, 2002
Phase I escalation of gemcitabine combined with protracted oral etoposide in gynecologic malignancies: A Gynecologic Oncology Group studyAgustin A Garcia, Michael A Bookman, Lorna Rodriguez-Rodriguez, et al.
Cancer|September 24, 2010
Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a Gynecologic Oncology Group studyRichard J Zaino, Mark F Brady, Subodh M Lele, et al.
Pageof 11